Trial Profile

An open-label, randomized, 5-treatment, 5-way crossover study to compare bioavailability and cardiovascular effects of intranasal epinephrine nasal spray versus IM epinephrine

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2024 Results assessing pharmacokinetics and safety of repeat dosing with Epinephrine Nasal Spray presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
09 Nov 2023 According to a Bryn Pharma media release, data from this study will be presented during the 2023 American College of Allergy Asthma and Immunology Annual Scientific Meeting (ACAAI).
09 Nov 2023 Results presentedin in a Bryn Pharma Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com